Ph.D. Niro Ramachandran - 23 Mar 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Business Officer
Signature
/s/ Niro Ramachandran, Ph.D., by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
23 Mar 2024
Net transactions value
-$9,609
Form type
4
Filing time
25 Mar 2024, 17:14:34 UTC
Previous filing
01 Mar 2024
Next filing
21 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Tax liability $9,609 -2,006 -0.96% $4.79 207,924 23 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to cover taxes on a restricted stock unit award previously granted March 23, 2022, which vests in four (4) annual equal installments beginning on March 23, 2023 and annually thereafter until fully vested.